

Yasoo Health Ltd's E!INFLATREAT chosen as one of best practice research projects

May 12, 2009 -Yasoo Health Ltd, a subsidiary of Yasoo Health Inc., reported today that its Eureka research grant E!INFLATREAT was chosen as one of the 24 best practice research projects in a recent survey performed for the European 7th Framework Programme entitled "Use and Diffuse"(www.useanddiffuse.eu). A total of 222 projects were surveyed to explore their dissemination and exploitation practices with innovation outputs. The results of the survey can be found in the following webpage:

<http://www.useanddiffuse.eu/default.aspx?articleID=17316&heading=Project%20Highlights>

The strategic objective of the 'Use and Diffuse' project is to enhance the dissemination and exploitation of research results and facilitate the exchange of best practices in this area. The target groups are small and medium sized enterprises and RTD performers who have participated in research and development projects in previous Framework Programmes, as well as those planning to participate in RTD actions in the 7th Framework Programme, including programmes such as "Research for the benefit of SMEs". For the purposes of the research carried out during this project, 'Use and Diffuse' focused on the ICT and Health sectors. However, the results will without doubt be applicable to a whole host of industrial sectors. It is expected that this project will add significant value to the European research effort and its results will serve to enrich RTD activities involving SMEs.

The aim of the Eureka project E!INFLATREAT was to evaluate selected naturally occurring lipophilic antioxidants and their modified derivatives for their ability to ameliorate inflammation associated with Inflammatory Bowel Disease (IBD). The ultimate goal is the development of a novel nutraceutical product for the management and adjunctive therapy of IBD. More details on the project can be found on the following webpage: www.inflatreat.com